- Home
- ACHC vs MDXG Comparison
ACHC vs MDXG Comparison
Compare ACHC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | MDXG |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2011 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ACHC | MDXG |
|---|---|---|
| Price | $25.59 | $3.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $22.67 | $9.00 |
| AVG Volume (30 Days) | ★ 3.1M | 1.8M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $3,312,769,000.00 | $418,630,000.00 |
| Revenue This Year | $5.08 | N/A |
| Revenue Next Year | $5.98 | $13.02 |
| P/E Ratio | $513.20 | ★ N/A |
| Revenue Growth | 5.04 | ★ 19.99 |
| 52 Week Low | $11.43 | $3.03 |
| 52 Week High | $30.20 | $7.99 |
Technical Indicators
Market Signals| Indicator | ACHC | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 48.95 |
| Support Level | $22.14 | $3.11 |
| Resistance Level | $27.74 | $7.39 |
| Average True Range (ATR) | 1.77 | 0.20 |
| MACD | -0.40 | 0.07 |
| Stochastic Oscillator | 45.59 | 88.65 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.